Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink

International Journal of Cancer

Volumn 138, Issue 9, 2016, Pages 2146-2153

  McGlynn, Katherine A ^a   Hagberg, Katrina ^b   Chen, Jie ^a   Braunlin, Megan ^a   Graubard, Barry I ^a   Suneja, Neha ^b   Jick, Susan ^b   Sahasrabuddhe, Vikrant V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

liver cancer; menopausal hormone therapy

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; ARTICLE; CANCER RESEARCH; CANCER RISK; CASE CONTROL STUDY; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HORMONAL THERAPY; HUMAN; LIVER CANCER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; AGED; ESTROGEN THERAPY; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; ODDS RATIO; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; ODDS RATIO; UNITED KINGDOM;

EID: 84958834847     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29960     Document Type: Article

References (33)

1. Ferlay J, Soerjomatarm I, Ervik M, et al,. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Last Available from: http://globocan.iarc.fr
2. Cameron R, Imaida K, Ito N., Promotive effects of ethinyl estradiol in hepatocarcinogenesis initiated by diethylnitrosamine in male rats. Gan 1981; 72: 339-40.
3. Yager JD, Jr, Yager R., Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980; 40: 3680-5.
4. Wanless IR, Medline A., Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982; 46: 313-20.
5. Nakatani T, Roy G, Fujimoto N, et al,. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 2001; 92: 249-56.
6. Vesselinovitch SD, Itze L, Mihailovich N, et al,. Modifying role of partial hepatectomy and gonadectomy in ethylnitrosourea-induced hepatocarcinogenesis. Cancer Res 1980; 40: 1538-42.
7. Naugler WE, Sakurai T, Kim S, et al,. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
8. IARC monographs on the evaluation of the carcinogenic risks to humans: combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy 2007; 91.
9. Bassuk SS, Manson JE., Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol 2015; 25: 193-200.
10. Beral V, Gaitskell K, Hermon C, et al,., Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385: 1835-42.
11. Benson VS, Kirichek O, Beral V, et al,. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015; 136: 2369-77.
12. Greiser CM, Greiser EM, Doren M., Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas 2010; 65: 198-204.
13. Green J, Czanner G, Reeves G, et al,. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 2012; 130: 2387-96.
14. Landgren O, Zhang Y, Zahm SH, et al,. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2342-7.
15. Fernandez E, Gallus S, Bosetti C, et al,. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105: 408-12.
16. Persson I, Yuen J, Bergkvist L, et al,. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32.
17. Tavani A, Negri E, Parazzini F, et al,. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993; 67: 635-7.
18. McGlynn KA, Sahasrabuddhe VV, Campbell PT, et al,. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer 2015; 112 Suppl: 1266-72.
19. Yu MC, Tong MJ, Govindarajan S, et al,. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83: 1820-6.
20. Lawson DH, Sherman V, Hollowell J., The General Practice Research Database. Scientific and Ethical Advisory Group. Qjm 1998; 91: 445-52.
21. Jick H, Jick SS, Derby LE., Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
22. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al,. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
23. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR., Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
24. Wang C, Wang X, Gong G, et al,. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-48.
25. Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al,. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012; 104: 1808-14.
26. Hassan MM, Curley SA, Li D, et al,. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-46.
27. McGlynn KA, Hagberg K, Chen J, et al,. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst 2015; 107:
28. Clark JM, Brancati FL, Diehl AM., Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
29. Kanaya AM, Herrington D, Vittinghoff E, et al,., Heart, Estrogen/Progestin Replacement S. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1-9.
30. McKenzie J, Fisher BM, Jaap AJ, et al,. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 2006; 65: 40-4.
31. Yu MW, Chang HC, Chang SC, et al,. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 2003; 38: 1393-400.
32. Yamamoto R, Tatsuta M, Terada N., Suppression by oestrogen of hepatocellular tumourigenesis induced in mice by 3'-methyl-4-dimethylaminoazobenzene. Br J Cancer 1993; 68: 303-7.
33. Yamamoto R, Iishi H, Tatsuta M, et al,. Correlation between serum prolactin levels and hepatocellular tumorigenesis induced by 3'-methyl-4-dimethylaminoazobenzene in mice. Br J Cancer 1995; 72: 17-21.